Post-earnings recap
Reported
Mon, Aug 10, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Xenon Pharmaceutical's earnings report showed a significant miss on EPS, which contributed to a 1.18% decline in stock price. The absence of revenue figures and guidance indicates uncertainty about the company's financial outlook. Investors may be concerned about the company's ability to generate revenue in the near term, especially given the defensive tone from management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.07 | N/A | -600.00% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding future performance due to the lack of revenue guidance. They emphasized their commitment to ongoing clinical development.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focused on advancing its clinical programs amid challenging market conditions.